Literature DB >> 16682722

When the risk of febrile neutropenia is 20%, prophylactic colony-stimulating factor use is clinically effective, but is it cost-effective?

Jared R Adams, Cara Angelotta, Charles L Bennett.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16682722     DOI: 10.1200/JCO.2006.05.6812

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  3 in total

Review 1.  Prophylactic Measures During Induction for Acute Myeloid Leukemia.

Authors:  Matthew W McCarthy; Thomas J Walsh
Journal:  Curr Oncol Rep       Date:  2017-03       Impact factor: 5.075

2.  Risk-adapted strategy for the management of febrile neutropenia in cancer patients.

Authors:  Jean Klastersky; Marianne Paesmans
Journal:  Support Care Cancer       Date:  2007-02-09       Impact factor: 3.603

3.  Prophylactic G-CSF in patients with early-stage breast cancer: a health economic review.

Authors:  P Trueman
Journal:  Br J Cancer       Date:  2009-09       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.